Literature DB >> 21301777

Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.

Alexander Hamilton1, Margareth Ozelo, Jayne Leggo, Colleen Notley, Hannah Brown, Juan Pablo Frontroth, Anne Angelillo-Scherrer, Fariba Baghaei, Said M Enayat, Emmanuel Favaloro, David Lillicrap, Maha Othman.   

Abstract

Less than 50 patients are reported with platelet type von Willebrand disease (PT-VWD) worldwide. Several reports have discussed the diagnostic challenge of this disease versus the closely similar disorder type 2B VWD. However, no systematic study has evaluated this dilemma globally. Over three years, a total of 110 samples/data from eight countries were analysed. A molecular approach was utilised, analysing exon 28 of the von Willebrand factor (VWF) gene, and in mutation negative cases the platelet GP1BA gene. Our results show that 48 cases initially diagnosed as putative type 2B/PT-VWD carried exon 28 mutations consistent with type 2B VWD, 17 carried GP1BA mutations consistent with a PT-VWD diagnosis, three had other VWD types (2A and 2M) and five expressed three non-previously published exon 28 mutations. Excluding 10 unaffected family members and one acquired VWD, 26 cases did not have mutations in either genes. Based on our study, the percentage of type 2B VWD diagnosis is 44% while the percentage of misdiagnosis of PT-VWD is 15%. This is the first large international study to investigate the occurrence of PT-VWD and type 2B VWD worldwide and to evaluate DNA analysis as a diagnostic tool for a large cohort of patients. The study highlights the diagnostic limitations due to unavailability/poor application of RIPA and related tests in some centres and proposes genetic analysis as a suitable tool for the discrimination of the two disorders worldwide. Cases that are negative for both VWF and GP1BA gene mutations require further evaluation for alternative diagnoses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301777     DOI: 10.1160/TH10-08-0523

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

Review 2.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

3.  Hyperactive GPIb-von Willebrand factor interaction as cause of thrombocytopenia: altered platelet formation versus clearance.

Authors:  Kathleen Freson
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

Review 4.  Diagnosing von Willebrand disease: genetic analysis.

Authors:  Anne Goodeve
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Genetics of familial forms of thrombocytopenia.

Authors:  Carlo L Balduini; Anna Savoia
Journal:  Hum Genet       Date:  2012-08-11       Impact factor: 4.132

Review 6.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

Review 7.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

8.  Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project.

Authors:  Almudena Pérez-Rodríguez; Javier Batlle; Irene Corrales; Nina Borràs; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Nira Navarro; Carmen Altisent; Rocío Pérez-Montes; Shally Marcellini; Ana Moreto; Sonia Herrero; Inmaculada Soto; Nuria Fernández Mosteirín; Víctor Jiménez-Yuste; Nieves Alonso; Aurora de Andrés Jacob; Emilia Fontanes; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Nerea Castro Quismondo; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Maria Tenorio; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Manuela Dobón; Carlos Aguilar; Fernando Batlle; Francisco Vidal; María Fernanda López-Fernández
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

9.  Pseudo (platelet-type) von Willebrand disease in pregnancy: a case report.

Authors:  Neetu Grover; Vincent Boama; Munazzah Rifat Chou
Journal:  BMC Pregnancy Childbirth       Date:  2013-01-17       Impact factor: 3.007

10.  Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.

Authors:  Nina Borràs; Javier Batlle; Almudena Pérez-Rodríguez; María Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; Rafael Parra; María Eva Mingot-Castellano; Ignacia Balda; Carme Altisent; Rocío Pérez-Montes; Rosa María Fisac; Gemma Iruín; Sonia Herrero; Inmaculada Soto; Beatriz de Rueda; Víctor Jiménez-Yuste; Nieves Alonso; Dolores Vilariño; Olga Arija; Rosa Campos; María José Paloma; Nuria Bermejo; Rubén Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Lizheidy Sarmiento; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María César; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Rosa Cornudella; Carlos Aguilar; Francisco Vidal; Irene Corrales
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.